Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemiplimab + dabrafenib + trametinib
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the PD-1 monoclonal antibody cemiplimab, the BRAF inhibitor dabrafenib, and the MEK inhibitor trametinib. It is being investigated for the treatment of BRAF-V600E mutant anaplastic thyroid cancer (ATC), particularly in patients who have progressed on prior BRAF/MEK inhibitor therapy. The rationale is that BRAF and MEK inhibition may enhance the tumor's sensitivity to immune checkpoint blockade by modulating the tumor microenvironment and increasing antigen expression. Cemiplimab acts as an immune checkpoint inhibitor by blocking the PD-1 receptor on T-cells, while dabrafenib and trametinib target the MAPK signaling pathway to inhibit tumor cell proliferation.
- Brand names
- Libtayo + Tafinlar + Mekinist
- Other names
- Cemiplimab with Dabrafenib and Trametinib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDCD1 (Programmed cell death protein 1 receptor)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on cemiplimab + dabrafenib + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemiplimab + dabrafenib + trametinib.